Rezdiffra Maintained Efficacy Across Genetic MASH Risk Variants
A study found that common genetic variants do not affect how well this MASH treatment works for patients.
Updated on Oct. 6, 2026 in Diabetes
Live Poll
Do you trust that new medical treatments are sufficiently tested for patients with different genetic backgrounds?
A new secondary analysis of 738 patients from the MAESTRO-NASH trial confirmed that the drug Rezdiffra shows consistent results across multiple genetic risk variants for metabolic dysfunction-associated steatohepatitis (MASH). These findings provide reassurance for patients worried that their specific genetic makeup might influence treatment success.
Why it matters
Understanding how genetic factors influence treatment response is critical as clinicians move toward more personalized approaches for managing chronic liver disease. This study clarifies that common risk alleles do not act as barriers to the efficacy of this thyroid hormone receptor-beta agonist.
The analysis evaluated data from 738 patients who completed 52-week liver biopsies, demonstrating consistent MASH resolution and fibrosis improvement regardless of PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7 genetic variants. These findings compare treatment success against placebo cohorts.
The players
Madrigal Pharmaceuticals
A biopharmaceutical company headquartered in Conshohocken, Pennsylvania, focused on the development of therapies for non-alcoholic steatohepatitis.
Rezdiffra
A thyroid hormone receptor-beta agonist approved for the treatment of patients with MASH.
The details
Rezdiffra works by targeting the thyroid hormone receptor-beta in the liver, a process that helps regulate metabolism and reduce toxic lipid accumulation. The study compared the drug to a placebo to determine if genetic variants that typically predispose individuals to liver disease might interfere with this metabolic pathway. The results showed that the drug maintained its therapeutic activity in lowering liver inflammation and scarring across diverse genetic profiles.
Timeline
May 2026: Madrigal Pharmaceuticals added MGL-0795 to its development pipeline.
Week 52: Trial participants completed their final follow-up liver biopsies.
October 6, 2026: Madrigal Pharmaceuticals announced the publication of the secondary analysis.
Health Landscape
This analysis builds upon the foundational results of the MAESTRO-NASH trial to refine the clinical application of precision medicine in liver health. It differentiates Rezdiffra from previous therapies by demonstrating that treatment efficacy remains stable despite the influence of common genetic predispositions.
Patients with MASH should discuss with their doctor whether genetic testing is necessary for their treatment plan, as this study suggests current therapies remain effective regardless of these specific risk variants. Always consult a physician to understand how specific genetic factors may or may not affect your personalized care.
The takeaway
This analysis confirms that genetic markers do not necessarily dictate how a patient responds to this MASH treatment. Speak with your healthcare provider about appropriate diagnostic testing if you are concerned about how your individual health profile affects your liver disease management.
Further reading
For more information on managing metabolic liver conditions, visit Diabetes.
Live Poll
Do you trust that new medical treatments are sufficiently tested for patients with different genetic backgrounds?
